NGM Biopharmaceuticals, Inc. (NGM)

NASDAQ: NGM · IEX Real-Time Price · USD
13.35
-0.23 (-1.69%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap1.06B
Revenue (ttm)n/a
Net Income (ttm)-125.24M
Shares Out79.26M
EPS (ttm)-1.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume290,540
Open13.50
Previous Close13.58
Day's Range12.98 - 13.58
52-Week Range10.49 - 29.58
Beta1.77
AnalystsBuy
Price Target35.70 (+167.4%)
Earnings DateMay 9, 2022

About NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for ...

IndustryPharmaceuticals
IPO DateApr 4, 2019
CEODavid Woodhouse
Employees225
Stock ExchangeNASDAQ
Ticker SymbolNGM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NGM stock is "Buy." The 12-month stock price forecast is 35.7, which is an increase of 167.42% from the latest price.

Price Target
$35.7
(167.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeut...

1 week ago - GlobeNewsWire

5 Graham's Lost Formula Biotech Stocks to Consider for May

After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.

Other symbols:MRNAREGNSGENTGTX
2 weeks ago - GuruFocus

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...

4 weeks ago - GlobeNewsWire

NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myelo...

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...

1 month ago - GlobeNewsWire

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcom...

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...

2 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Advanced programs across NGM Bio's pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022

2 months ago - GlobeNewsWire

NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...

2 months ago - GlobeNewsWire

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

3 months ago - Zacks Investment Research

NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy S...

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...

3 months ago - GlobeNewsWire

NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Met...

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...

4 months ago - GlobeNewsWire

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 ...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

5 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 2.63% and -1.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Is Good News Enough for You to Buy NGM on the Dip?

A drop in the overall market provides an opportunity for investors to pounce.

7 months ago - The Motley Fool

NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial

NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced preliminary findings from its ongoing Phase 1a/1b dose-escalation study of NGM120 in solid tumors. Related Link:   Raymond James Upgraded This Biopharm...

8 months ago - Benzinga

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside

Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:NGM) to Strong Buy from Outperform with a price target of $39, up from $27, almost 44% upside. Analyst Steven Seedhouse notes the validation...

8 months ago - Benzinga

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publica...

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

8 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -23.08% and -24.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

What Makes NGM Biopharmaceuticals (NGM) a New Buy Stock

NGM Biopharmaceuticals (NGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets

NGM Biopharmaceuticals Inc (NASDAQ: NGM) has amended and restated an agreement with Merck & Co Inc (NYSE: MRK) to extend their ongoing collaboration through March 2024 with a narrower scope.  The collab...

Other symbols:MRK
10 months ago - Benzinga

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular an...

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known as...

10 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?

NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...

11 months ago - Zacks Investment Research